



UNIVERSITY OF LEEDS

This is a repository copy of *Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/155919/>

Version: Supplemental Material

---

**Article:**

Thorneloe, RJ, Hall, LH, Walter, FM et al. (3 more authors) (2020) Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy. *Cancer Prevention Research*, 13 (4). pp. 411-422. ISSN 1940-6207

<https://doi.org/10.1158/1940-6207.CAPR-19-0424>

---

© 2020, American Association for Cancer Research. This is an author produced version of a paper published in *Cancer Prevention Research*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table S1. Univariable comparison of retention (n = 408)**

Mean ( $\pm$ SD) for continuous variables; % (n) for categorical variables	Baseline only (n = 150)	Baseline and 3 months (n = 258)	P-value
<b>Knowledge about harms and benefits</b>			
Yes	12.6 (17)	17.3 (43)	0.242
No	87.4 (118)	82.7 (205)	
<b>Satisfaction with healthcare professional</b>			
Satisfaction score, mean $\pm$ SD	19.30 $\pm$ 3.68	19.30 $\pm$ 3.83	0.987
<b>Received a leaflet about tamoxifen</b>			
Yes	68.0 (102)	72.9 (188)	0.310
No/unsure	32.0 (48)	27.1 (70)	
<b>Felt informed about tamoxifen</b>			
Yes	80.3 (118)	91.0 (233)	<b>0.003</b>
No	19.7 (29)	9.0 (23)	

P-value tests for significant differences between the 'baseline' and 'baseline and 3-month' cohorts using  $\chi^2$  tests and t-tests.

**Table S2. Sensitivity analysis: Knowledge about benefits and  $\geq 2$  harms of tamoxifen by participant characteristics and univariable and multivariable logistic regression model (n =317)**

Knowledge about benefits and $\geq 2$ harms of tamoxifen (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
<b>Age</b>					
$\leq 35$ years	25.6 (10)	0.78 (0.34 – 1.79)	0.556	0.73 (0.23 – 2.26)	0.579
36 – 49 years	32.9 (80)	1.11 (0.67 – 1.83)	0.687	0.71 (0.37 – 1.36)	0.303
$\geq 50$ years	30.7 (31)	Ref		Ref	
<b>Children</b>					
Yes	33.1 (98)	1.38 (0.81 – 2.35)	0.240	1.61 (0.76 – 3.41)	0.219
No	26.4 (23)	Ref		Ref	
<b>Ethnic group*</b>					
White	31.2 (114)	-	-	-	-
Other	42.9 (6)	-	-	-	-
<b>Education level</b>					
Degree or above	43.3 (74)	2.67 (1.71 – 4.17)	$\leq 0.001$	2.95 (1.68 – 5.18)	$\leq 0.001$
Below degree level	22.2 (46)	Ref		Ref	
<b>Health status</b>					
Poor*	33.3 (5)	-	-	-	-
Fair	16.2 (12)	0.39 (0.17 – 0.88)	<b>0.023</b>	0.47 (0.18 – 1.18)	0.108
Good	36.2 (83)	1.14 (0.62 – 2.07)	0.675	1.14 (0.57 – 2.29)	0.713
Excellent	33.3 (20)	Ref		Ref	
<b>Risk level</b>					
Moderate	35.5 (81)	1.57 (1.00 – 2.47)	0.052	1.79 (1.03 – 3.14)	<b>0.041</b>
High	26.0 (39)	Ref		Ref	
Unclear*	20.0 (1)	-	-	-	-
<b>SES</b>					
Low (most deprived)	28.6 (32)	0.77 (0.45 – 1.33)	0.354	1.06 (0.55 – 2.04)	0.860
Middle	31.5 (40)	0.89 (0.53 – 1.49)	0.657	0.900 (0.48 – 1.70)	0.742
High (least deprived)	34.1 (47)	Ref		Ref	

<b>Employment</b>					
Full-time	31.0 (102)	Ref		Ref	
All other employments	35.2 (19)	1.21 (0.66 – 2.21)	0.540	1.88 (0.91 – 3.90)	0.089
<b>Marital status</b>					
Married or cohabiting	32.3 (91)	1.06 (0.65 – 1.75)	0.807	1.15 (0.59 – 2.26)	0.686
Unmarried	30.9 (30)	Ref		Ref	
<b>Numeracy</b>					
Good numeracy	34.0 (104)	1.99 (1.05 – 3.74)	<b>0.034</b>	2.43 (1.09 – 5.40)	<b>0.030</b>
Poor numeracy	20.6 (14)	Ref		Ref	
<b>Received a leaflet about tamoxifen</b>					
Yes	34.7 (95)	1.69 (1.02 – 2.81)	<b>0.041</b>	1.14 (0.61 – 2.12)	0.684
No/unsure	23.9 (26)	Ref		Ref	
<b>Satisfaction with healthcare professional</b>					
Satisfaction score, mean ± SD	19.44 (3.44)	1.02 (0.96 – 1.08)	0.629	0.99 (0.93 – 1.07)	0.836
<b>Felt informed about tamoxifen</b>					
Yes	34.5 (115)	3.69 (1.52 – 8.95)	<b>0.004</b>	3.73 (1.18 – 11.79)	<b>0.025</b>
No	12.5 (6)	Ref		Ref	

\*category not included in univariable and multivariable analyses due to insufficient cases.

\*= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and at least two of the three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer). In total, 31.6% (121) of women identified the benefit and ≥ 2 harms of tamoxifen.

**Table S3. Knowledge about the potential harms and benefits of tamoxifen by participant characteristics and univariable and multivariable logistic regression model, with missing data reported as poor knowledge (n=332)**

Good knowledge <sup>+</sup> (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
<b>Age</b>					
≤ 35 years	9.8 (4)	0.66 (0.21 – 2.13)	0.490	0.50 (0.11 – 2.43)	0.393
36 – 49 years	15.8 (41)	1.18 (0.62 – 2.24)	0.611	0.69 (0.30 – 1.59)	0.387
≥ 50 years	13.9 (15)	Ref		Ref	
<b>Children</b>					
Yes	15.3 (48)	1.23 (0.63 – 2.43)	0.545	1.47 (0.57 – 3.76)	0.425
No	12.8 (12)	Ref		Ref	
<b>Ethnic group*</b>					
White	14.3 (55)	-	-	-	-
Other	22.2 (4)	-	-	-	-
<b>Education level</b>					
Degree or above	21.6 (38)	2.50 (1.42 – 4.42)	<b>0.002</b>	2.47 (1.23 – 4.97)	<b>0.011</b>
Below degree level	9.9 (22)	Ref		Ref	
<b>Health status</b>					
Poor*	18.8 (3)	-	-	-	-
Fair	6.4 (5)	0.38 (0.12 – 1.19)	0.096	0.40 (0.11 – 1.46)	0.166
Good	17.5 (42)	1.19 (0.56 – 2.52)	0.653	1.16 (0.50 – 2.68)	0.737
Excellent	15.2 (10)	Ref		Ref	
<b>Risk level</b>					
Moderate	17.7 (43)	1.80 (0.98 – 3.28)	0.056	1.94 (0.94 – 4.00)	0.075
High	10.7 (17)	Ref		Ref	
Unclear*	0.0 (0)	-	-	-	-
<b>SES</b>					
Low (most deprived)	13.3 (16)	0.84 (0.42 – 1.68)	0.630	1.01 (0.44 – 2.29)	0.986
Middle	14.5 (19)	0.95 (0.49 – 1.83)	0.872	0.93 (0.42 – 2.06)	0.862
High (least deprived)	15.3 (23)	Ref		Ref	

<b>Employment</b>					
Full-time	15.2 (53)	Ref		Ref	
All other employments	11.7 (7)	0.72 (0.31 – 1.67)	0.444	1.13 (0.44 – 2.91)	0.799
<b>Marital status</b>					
Married or cohabiting	15.4 (46)	1.14 (0.59 – 2.17)	0.701	1.00 (0.44 – 2.29)	0.998
Unmarried	13.6 (14)	Ref		Ref	
<b>Numeracy</b>					
Good numeracy	18.0 (58)	7.70 (1.83 – 32.30)	<b>0.005</b>	6.14 (1.39 – 27.09)	<b>0.017</b>
Poor numeracy	2.8 (2)	Ref		Ref	
<b>Received a leaflet about tamoxifen</b>					
Yes	16.9 (49)	1.98 (0.99 – 3.95)	0.054	1.52 (0.65 – 3.55)	0.334
No/unsure	9.3 (11)	Ref		Ref	
<b>Satisfaction with healthcare professional</b>					
Satisfaction score, mean ± SD	19.34 ± 3.55	1.00 (0.93 – 1.08)	0.936	0.97 (0.89 – 1.06)	0.554
<b>Felt informed about tamoxifen</b>					
Yes	16.5 (58)	4.95 (1.17 – 20.91)	<b>0.030</b>	5.49 (0.69 – 43.73)	0.108
No	3.8 (2)	Ref		Ref	

\*category not included in univariable and multivariable analyses due to insufficient cases.

\*= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).

**Table S4. Still deciding about tamoxifen on the subjective decision quality scale, by participant characteristics and univariable and multivariable logistic regression model (n=216)**

Still deciding (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
<b>Age</b>					
≤ 35 years	37.0 (10)	0.55 (0.22 – 1.40)	0.208	0.57 (0.17 – 1.91)	0.361
36 – 49 years	41.1 (69)	0.65 (0.36 – 1.17)	0.154	0.70 (0.34 – 1.44)	0.334
≥ 50 years	51.6 (32)	Ref		Ref	
<b>Children</b>					
Yes	43.8 (89)	1.14 (0.62 – 2.09)	0.683	0.94 (0.41 – 2.15)	0.878
No	40.7 (22)	Ref		Ref	
<b>Ethnic group</b>					
White	43.1 (106)	1.51 (0.37 – 6.19)	0.564	1.02 (0.21 – 5.05)	0.983
Other	33.3 (3)	Ref		Ref	
<b>Education level</b>					
Degree or above	35.9 (42)	0.59 (0.35 – 0.97)	<b>0.037</b>	0.72 (0.38 – 1.39)	0.329
Below degree level	48.9 (68)	Ref		Ref	
<b>Health status</b>					
Poor	45.5 (5)	1.62 (0.43 – 6.11)	0.481	2.92 (0.58 – 14.60)	0.193
Fair	44.7 (21)	1.57 (0.68 – 3.60)	0.292	1.56 (0.59 – 4.14)	0.373
Good	45.3 (68)	1.61 (0.81 – 3.18)	0.174	1.31 (0.58 – 2.96)	0.512
Excellent	34.0 (16)	Ref		Ref	
<b>Risk level</b>					
Moderate	37.6 (59)	0.58 (0.35 – 0.96)	<b>0.035</b>	0.70 (0.38 – 1.29)	0.251
High	51.0 (50)	Ref		Ref	
Unclear*	2 (100)	-	-	-	-
<b>SES</b>					
Low (most deprived)	45.9 (28)	1.08 (0.58 – 2.04)	0.804	0.69 (0.31 – 1.52)	0.360
Middle	40.0 (34)	0.85 (0.48 – 1.52)	0.584	0.55 (0.27 – 1.13)	0.105
High (least deprived)	43.9 (47)	Ref		Ref	

<b>Employment</b>					
Full-time	43.2 (95)	Ref		Ref	
All other employments	43.2 (16)	1.00 (0.50 – 2.03)	0.994	1.07 (0.47 – 2.48)	0.868
<b>Marital status</b>					
Married or cohabiting	41.6 (82)	0.74 (0.41 – 1.32)	0.307	0.96 (0.44 – 2.06)	0.909
Unmarried	49.2 (29)	Ref		Ref	
<b>Numeracy</b>					
Good numeracy	42.3 (88)	0.84 (0.44 – 1.63)	0.613	1.03 (0.46 – 2.33)	0.940
Poor numeracy	46.5 (20)	Ref		Ref	
<b>Received a leaflet about tamoxifen</b>					
Yes	44.4 (83)	1.20 (0.69 – 2.09)	0.528	1.22 (0.61 – 2.45)	0.573
No/unsure	40.0 (28)	Ref		Ref	
<b>Satisfaction with healthcare professional</b>					
Satisfaction score, mean $\pm$ SD	18.28 $\pm$ 3.57	0.88 (0.82 – 0.95)	<b>0.001</b>	0.88 (0.81 – 0.96)	<b>0.003</b>
<b>Felt informed about tamoxifen</b>					
Yes	40.8 (95)	0.37 (0.15 – 0.90)	<b>0.029</b>	0.64 (0.21 – 1.90)	0.419
No	65.2 (15)	Ref		Ref	
<b>Knowledge about harms and benefits</b>					
Yes	38.6 (17)	0.81 (0.41 – 1.57)	0.522	1.04 (0.47 – 2.33)	0.919
No	43.9 (90)	Ref		Ref	

\*category not included in univariable and multivariable analyses due to insufficient cases.